Literature DB >> 33941929

Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands.

Joshua D Cohen1,2,3,4,5, Christopher Douville1,2,3,4, Jonathan C Dudley1,2,3,4, Brian J Mog1,2,3,4,5, Maria Popoli1,2,3,4, Janine Ptak1,2,3,4, Lisa Dobbyn1,2,3, Natalie Silliman1,2,3,4, Joy Schaefer1,2,3, Jeanne Tie6,7,8,9, Peter Gibbs6,8,9, Cristian Tomasetti2,10, Nickolas Papadopoulos11,12,13, Kenneth W Kinzler14,15,16, Bert Vogelstein17,18,19,20.   

Abstract

Identification and quantification of low-frequency mutations remain challenging despite improvements in the baseline error rate of next-generation sequencing technologies. Here, we describe a method, termed SaferSeqS, that addresses these challenges by (1) efficiently introducing identical molecular barcodes in the Watson and Crick strands of template molecules and (2) enriching target sequences with strand-specific PCR. The method achieves high sensitivity and specificity and detects variants at frequencies below 1 in 100,000 DNA template molecules with a background mutation rate of <5 × 10-7 mutants per base pair (bp). We demonstrate that it can evaluate mutations in a single amplicon or simultaneously in multiple amplicons, assess limited quantities of cell-free DNA with high recovery of both strands and reduce the error rate of existing PCR-based molecular barcoding approaches by >100-fold.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33941929      PMCID: PMC8627329          DOI: 10.1038/s41587-021-00900-z

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  6 in total

1.  OPUSeq simplifies detection of low-frequency DNA variants and uncovers fragmentase-associated artifacts.

Authors:  Alisa Alekseenko; Jingwen Wang; Donal Barrett; Vicent Pelechano
Journal:  NAR Genom Bioinform       Date:  2022-06-27

2.  Liquid biopsy in gliomas: A RANO review and proposals for clinical applications.

Authors:  Riccardo Soffietti; Chetan Bettegowda; Ingo K Mellinghoff; Katherine E Warren; Manmeet S Ahluwalia; John F De Groot; Evanthia Galanis; Mark R Gilbert; Kurt A Jaeckle; Emilie Le Rhun; Roberta Rudà; Joan Seoane; Niklas Thon; Yoshie Umemura; Michael Weller; Martin J van den Bent; Michael A Vogelbaum; Susan M Chang; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

Review 3.  Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics.

Authors:  Ping Song; Lucia Ruojia Wu; Yan Helen Yan; Jinny X Zhang; Tianqing Chu; Lawrence N Kwong; Abhijit A Patel; David Yu Zhang
Journal:  Nat Biomed Eng       Date:  2022-01-31       Impact factor: 29.234

4.  Calibration-free NGS quantitation of mutations below 0.01% VAF.

Authors:  Peng Dai; Lucia Ruojia Wu; Sherry Xi Chen; Michael Xiangjiang Wang; Lauren Yuxuan Cheng; Jinny Xuemeng Zhang; Pengying Hao; Weijie Yao; Jabra Zarka; Ghayas C Issa; Lawrence Kwong; David Yu Zhang
Journal:  Nat Commun       Date:  2021-10-21       Impact factor: 14.919

5.  A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.

Authors:  Sina Vatandoust; David Wattchow; Luigi Sposato; Michael Z Michael; John Leung; Kirsten Gormly; Gang Chen; Erin L Symonds; Jeanne Tie; Lito Electra Papanicolas; Susan Woods; Val Gebski; Kelly Mead; Aleksandra Kuruni; Christos S Karapetis
Journal:  BMC Cancer       Date:  2022-03-01       Impact factor: 4.430

6.  Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays.

Authors:  Lei Chen; Anna Eriksson; Simone Weström; Tatjana Pandzic; Sören Lehmann; Lucia Cavelier; Ulf Landegren
Journal:  Nat Commun       Date:  2022-07-12       Impact factor: 17.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.